Table 2. Journals and impact factor scores by funding source (N=75).
Journal | Impact factor (2010) |
Industry-sponsored studies
|
Non-profit/ government studies
|
No funding/ none disclosure
|
|||
---|---|---|---|---|---|---|---|
Circulation | 14.8 | 1 | 0 | 0 | |||
J Am Coll Cardiol | 14.3 | 1 | 0 | 0 | |||
Eur Heart J | 10.0 | 3 | 0 | 2 | |||
Int J Cardiol | 6.8 | 0 | 0 | 1 | |||
Am Heart J | 5.0 | 1 | 1 | 0 | |||
Heart | 4.7 | 0 | 1 | 0 | |||
Atherosclerosis | 4.1 | 1 | 0 | 0 | |||
Am J Cardiol | 3.7 | 3 | 1 | 1 | |||
Can J Cardiol | 2.2 | 1 | 1 | 0 | |||
Rev Esp Cardiol | 2.2 | 1 | 0 | 0 | |||
Arch Cardiovasc Dis | 1.2 | 1 | 0 | 0 | |||
Acta Cardiol | 0.6 | 1 | 0 | 0 | |||
Totalcardiovasc(n=22). | 14 (67%) | 3 (14%) | 4 (19%) | ||||
N Engl J Med | 53.5 | 1 | 0 | 0 | |||
JAMA | 30.0 | 1 | 1 | 0 | |||
Ann Intern Med | 16.7 | 0 | 2 | 0 | |||
BMJ | 13.5 | 2 | 0 | 1 | |||
Arch Intern Med | 10.6 | 0 | 1 | 1 | |||
CAMJ | 9.0 | 1 | 0 | 0 | |||
J Intern Med | 5.9 | 1 | 0 | 0 | |||
Med J Aust | 2.7 | 1 | 1 | 0 | |||
Curr Med Res Opin | 2.6 | 2 | 1 | 1 | |||
Totalmedicine(n=18) | 9 (50%) | 6 (33%) | 3 (17%) | ||||
Pharmacoeconomics | 3.4 | 6 | 0 | 0 | |||
Clin Ther | 2.5 | 2 | 0 | 0 | |||
Ann Pharmacother | 2.2 | 1 | 0 | 0 | |||
Clin Drug Investing | 1.6 | 1 | 0 | 0 | |||
Totalpharmacol(n=10). | 10 (100%) | 0(0%) | 0(0%) | ||||
Health Technol Assess | 4.2 | 0 | 3 | 0 | |||
Value Health | 2.3 | 3 | 0 | 0 | |||
Eur J Health Econ | 1.8 | 2 | 0 | 0 | |||
Health Policy | 1.4 | 0 | 0 | 1 | |||
Totalhealthpolicy(n=9) | 5 (56%) | 3 (33%) | 1 (11%) | ||||
Diabetes care | 7.1 | 1 | 0 | 0 | |||
Diabetologia | 7.0 | 2 | 0 | 0 | |||
Totalendocrin(n=3). | 3 (100%) | 0(0%) | 0(0%) | ||||
Rev Neurol | 1.2 | 1 | 0 | 0 | |||
Other journals* | – | 6 | 1 | 5 | |||
Totalothers(n=13) | 7 (54%) | 1 (8%) | 5 (38%) |
Note: PubMed/MEDLINE and Index Medicus abbreviations of journal titles are used.
* Journals not included in the 2010 Journal Citation Report.